Pregnancy loss: miscarriage, stillbirth, recurrent loss, assessment and support

Separate timing, tissue findings and recurrence

Symptoms need assessment before assuming what has happened

Contact the pregnancy-care team promptly for bleeding, unusual discharge or fluid leakage. Heavy bleeding with severe abdominal or shoulder pain, faintness or loss of consciousness needs emergency assessment. These symptoms can have different causes and can require immediate treatment. Tests may include ultrasound and blood or urine tests. A diagnosis should describe what is known and what remains uncertain, rather than treating any bleeding or a positive pregnancy test alone as proof of the type of loss.[1]

Confirmed early loss can have several management options

RCOG explains that complete miscarriage may need no additional treatment, while incomplete or missed miscarriage may be managed by waiting, medicines or an operation. Choice depends on findings, symptoms and preferences, with clear follow-up and contact instructions. Waiting can involve pain and bleeding and may not complete the process. Ask what to expect, how completion will be checked and when to seek urgent help.[2]

Published questions

A loss does not establish personal blame

Many miscarriages relate to how the pregnancy develops, and a specific cause is often unknown. A risk factor does not show that someone caused their loss or that it was preventable.[1]

A trial supports a particular medical-management combination

The 2020 MifeMiso trial randomized 711 participants with ultrasound-confirmed missed miscarriage in the first fourteen weeks who chose medical management. Mifepristone followed by misoprostol was compared with placebo followed by misoprostol. Failure to pass the gestational sac within seven days occurred in 17% versus 24%; subsequent surgery was needed in 17% versus 25%. This supports a defined clinical option, not self-diagnosis or an identical regimen for incomplete miscarriage, later loss or ectopic pregnancy. Medicine access, contraindications and local protocols require clinical review. A successful physical treatment does not measure emotional recovery.[7]

Stillbirth evaluation may help without finding every cause

The ACOG/SMFM consensus discusses placental examination, genetic evaluation and fetal autopsy as parts of stillbirth investigation. Even thorough assessment can leave the cause unexplained. Timing and method of delivery depend on gestational age, obstetric history, preferences and available expertise. A care team should explain choices and results, including the possible limits of testing. The consensus also supports emotional care and referral to bereavement, peer or mental-health services when helpful. Later loss therefore involves a different clinical pathway from an early-miscarriage medication trial.[4]

Definitions and population risk require context

CDC divides US stillbirth into early, late and term categories, beginning at twenty weeks. Other sources use different pregnancy-loss thresholds, so a gestational label should be explained in the local care and reporting system. CDC also describes unequal stillbirth rates and explicitly rejects treating racial differences as biological or genetic causes. Access to quality care, existing conditions and other contextual factors need investigation. A group risk association cannot identify why one person’s loss occurred, assign blame or establish that it was preventable.[3]

Repeated loss warrants a conversation about an appropriate evaluation

ESHRE’s 2023 guideline considers recurrent pregnancy loss after two or more pregnancy losses and emphasizes history and shared decisions about investigation. Recognized ectopic and molar pregnancies are excluded from that definition because they follow different pathways. Investigation does not always identify a treatable explanation. The guideline warns that testing can provide information without improving prognosis and that unproven interventions should not be assumed effective. Referral thresholds and available services differ; ask how your particular history fits the local pathway and what a proposed test would change.[5]

Distress can continue after physical symptoms improve

Farren and colleagues recruited 737 people with early pregnancy loss at three London hospitals for prospective questionnaires. Among respondents,29% met screening criteria for posttraumatic stress at one month and 18% at nine months. These were questionnaire thresholds, not confirmed clinical diagnoses. Response fell to 46% of enrolled participants by nine months, which can affect estimates; participants do not represent every family or culture. The study identifies an important support need, but it cannot show that everyone develops a disorder or that a particular counselling intervention works. A grief response and a clinical diagnosis require separate consideration.[8]

Possible explanations are not a guarantee of a remedy

RCOG describes recurrent miscarriage as three or more early miscarriages, even if healthy pregnancies occurred between them. It discusses uterine structure, genetic, hormonal and clotting-related factors among possible explanations. Many cases remain unexplained. A targeted investigation can sometimes identify a condition with useful treatment, but a broad panel or a plausible mechanism is not automatically beneficial. The guideline’s definition and ESHRE’s two-loss threshold serve different clinical frameworks. Neither should be used to tell someone that they cannot seek support or discuss evaluation before meeting a fixed count.[6]

Support can respect different feelings and readiness

RCOG describes recovery as highly individual and recognizes effects on partners, family and friends. Some people want to talk; others need privacy, practical help or time. Ask what support is welcome and avoid imposing a timetable or reassurance about a future pregnancy as a substitute for acknowledging this loss. A clinician can help when coping is difficult and discuss mental-health care or bereavement support.[2]

A distress percentage is not an instruction about how to feel

The cohort measured symptoms at specific follow-up points and had substantial nonresponse. Its averages cannot define normal grief or predict how long recovery should take. Support can be sought without waiting for a questionnaire threshold; this guide has not independently evaluated the best treatment for a particular person.[8]

References

1. Miscarriage

   Agency pregnancy loss guidance

   NHS · Content/publication date: 2026
   Accessed: 2026-10-14 UTC · Selected original page passages inspected
   Cited sections: UK timing definition, symptoms versus diagnosis, urgent/emergency advice, tests and support for partners

2. Early miscarriage

   Professional association patient guidance

   Royal College of Obstetricians and Gynaecologists · Content/publication date: 2026
   Accessed: 2026-10-14 UTC · Selected original page passages inspected
   Cited sections: Complete/incomplete/missed findings, confirmed-loss options, follow-up and individual emotional recovery

   First publishedSeptember 2016; displayed updateOctober 2026, day not stated. Page contains a 23-week general cutoff inconsistent with NHS 24/RCOG recurrent 24; that cutoff is not reproduced. Used for loss-specific findings/care/support.

3. About Stillbirth

   Agency condition explanation

   Centers for Disease Control and Prevention · Content/publication date: 2026
   Accessed: 2026-10-14 UTC · Selected original page passages inspected
   Cited sections: US 20-week definition, early/late/term categories and contextual health inequities

   Page publishedMay 2024; displayed 2026 update retained separately from check date. US definition is not exported as a universal threshold.

4. Obstetric Care Consensus No.10: Management of Stillbirth

   Professional association consensus

   American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine · Content/publication date: 2020
   Accessed: 2026-10-14 UTC · Original abstract and bibliographic record inspected; detailed consensus and underlying studies not independently appraised
   Cited sections: Evaluation, unexplained losses, individualized delivery and emotional/bereavement support

   Dated consensus used for assessment/support principles; no current numerical prevalence copied from its 2020 overview.

5. Recurrent Pregnancy Loss: ESHRE Guideline, Update 2022

   Professional association clinical guideline

   European Society of Human Reproduction and Embryology · Content/publication date: 2023
   Accessed: 2026-10-14 UTC · Selected original guideline PDF definition, organization-of-care and investigation passages inspected; full independent guideline appraisal not completed
   Cited sections: PDFpp 16–17 definition/exclusions, pp 22–23 care/testing purpose and investigation limitations

   Update named 2022, finalizedJanuary 2023 and issued 1 February 2023; no unverified 2026 update date supplied.

6. Recurrent miscarriage

   Professional association patient guidance

   Royal College of Obstetricians and Gynaecologists · Content/publication date: 2023
   Accessed: 2026-10-14 UTC · Selected original page passages inspected
   Cited sections: Three early losses, nonconsecutive history, explanations, investigations and unexplained prognosis/support

   Dated patient information; its scheduled three-year review period had elapsed at check, with no later date displayed in selected passages. Contrasted explicitly with ESHRE definition.

7. Mifepristone and misoprostol versus misoprostol alone for missed miscarriage: the MifeMiso trial

   Randomized controlled trial

   Chu and colleagues · Content/publication date: 2020
   Accessed: 2026-10-14 UTC · Original indexed abstract, bibliographic record and selected indexed original methods/results inspected; direct PubMed and PMC opens unavailable
   Cited sections: 711 randomized; ultrasound-confirmed missed miscarriage before 14 weeks; seven-day failure 17% vs 24% and surgery 17% vs 25%

   Later 2021 trial report concerns the same 711-person study and is not counted as independent evidence. No dosing or individualized regimen prescribed.

8. Posttraumatic stress, anxiety and depression following miscarriage and ectopic pregnancy: a multicenter prospective cohort study

   Prospective cohort study

   Farren and colleagues · Content/publication date: 2019
   Accessed: 2026-10-14 UTC · Original abstract, methods/results summary and bibliographic record inspected; full cohort report not independently appraised
   Cited sections: 737 recruited; questionnaire screening thresholds at 1/3/9 months, decline in response and comparison scope

   Online publication 13 December 2019; journal issueApril 2020. Screening thresholds are not confirmed diagnoses; follow-up nonresponse is retained.

Scope & review

Population

People with suspected or confirmed pregnancy loss, including partners and families; subtype-specific clinical pathways distinguished

Exposure or intervention

Assessment, confirmed-loss management, stillbirth/recurrent-loss evaluation and emotional support

Comparison

MifeMiso placebo-plus-misoprostol comparator; cohort viable-pregnancy controls; differing jurisdictional definitions not treated as equivalent populations

Outcomes

Diagnostic understanding, physical completion, subsequent intervention, evaluation information and distress/support needs

Timeframe

Acute symptoms and treatment through months of recovery and future-pregnancy planning

Jurisdiction

UK NHS/RCOG guidance, European ESHRE guideline, US CDC/ACOG/SMFM definitions and care; local access, reporting and treatment rules differ

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

What this article still leaves open

• Which evaluation changes care for a particular loss history?
• How do management outcomes vary outside the confirmed early missed-loss trial?
• Which support interventions are most useful to individuals and partners?
• How should local definitions, access and reporting requirements be explained sensitively?

Related reading

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.